NYSEMKT: PHGEBiomx Inc Stock
$0.35+0.05 (+16.67%)
Updated Apr 23, 2024
PHGE Price
$0.35
Fair Value Price
N/A
Market Cap
$19.11M
52 Week Low
$0.19
52 Week High
$0.86
P/E
-0.68x
P/B
6.2x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$26.17M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
7.12
Operating Cash Flow
-$21M
Beta
0.42
Next Earnings
May 10, 2024
Ex-Dividend
N/A
Next Dividend
N/A
PHGE Overview
BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PHGE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PHGE is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PHGE is poor value based on its book value relative to its share price (6.2x), compared to the US Biotechnology industry average (5.93x)
P/B vs Industry Valuation
PHGE is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more PHGE due diligence checks available for Premium users.
Be the first to know about important PHGE news, forecast changes, insider trades & much more!
PHGE News
Valuation
PHGE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.68x
Industry
16.46x
Market
41.92x
PHGE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.2x
Industry
5.93x
PHGE is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PHGE's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.5M
Profit Margin
0%
PHGE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$25.0M
Liabilities
$21.9M
Debt to equity
7.12
PHGE's short-term assets ($17.63M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PHGE's short-term assets ($17.63M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PHGE's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
PHGE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.2M
Investing
-$6.0k
Financing
-$1.3M
PHGE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PHGE vs Biotech Stocks
Biomx Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.